Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma

Malmer, Beatrice; Feychting, Maria; Lönn, Stefan; Lindström, Sara; Grönberg, Henrik; Ahlbom, Anders; Schwartzbaum, Judith A.; Auvinen, Anssi; Collatz-Christensen, Helle; Johansen, Christoffer; Kiuru, Anne; Mudie, Nadejda; Salminen, Tiina; Schoemaker, Minouk J.; Swerdlow, Anthony; Henriksson, Roger

doi:10.1007/s11060-006-9275-1

Cited by 58 publications

(41 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, these studies were treated as a mixed study at first, and then analyzed for high-grade and low-grade gliomas. The eight studies were conducted in different populations of various geographical locations: four were European populations (15,16,17,21), four were American (18,19,20,42) and only one was Asian (39). A stratified analysis for different geographical locations in high-grade gliomas was also conducted.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

TP53 codon 72 polymorphism and glioma risk: A meta-analysis

et al. 2011

View full text Add to dashboard Cite

Abstract. TP53 codon 72 polymorphism has been reported to affect regulatory networks central to glioma development. Although a number of published studies noted the association between TP53 codon 72 polymorphism and glioma risk, their conclusions were inconsistent. A meta-analysis was used to assess the possible association between TP53 codon 72 polymorphism and glioma risk. The PubMed databases were searched, relevant articles were identified and data were retrieved based on the inclusion criteria. The odds ratio (OR) and 95% confidence interval (95% CI) were determined on the pooled dataset. We retrieved eight different studies including 2,260 glioma cases and 3,506 controls. However, no association was found between the TP53 codon 72 polymorphism and glioma risk regarding the comparison between glioma cases and the controls. By further stratification based on criteria such as tumor grade, and the geographical location of the patients and the relevant controls, we found a significant association in the subgroup of patients with high-grade glioma in Europeans compared to controls in two models of TP53 codon 72 polymorphism, which include the dominant model [C/C + G/C vs. G/G: OR=1.35, 95% CI (1.14, 1.59), P=0.0005, P h =0.13] and the additive model [C allele vs. G allele: OR=1.16, 95% CI (1.02, 1.33), P=0.03, P h =0.37]. Our analysis suggests that TP53 codon 72 polymorphism is associated with an increased risk of high-grade glioma development in Europeans.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Studies exist regarding the association of the TP53 codon 72 polymorphism with susceptibility to the development of gliomas (15)(16)(17)(18)(19)(20)(21)42). However, the results obtained thus far were inconsistent.…”

Section: Introductionmentioning

confidence: 99%

TP53 codon 72 polymorphism and glioma risk: A meta-analysis

et al. 2011

View full text Add to dashboard Cite

show abstract

“…As shown in Figure 1, five eligible articles concerning WRAP53 rs2287499, including seven case-control datasets comprising 7107 cases and 10,737 controls were analyzed (Baynes et al, 2007;Garcia-Closas et al, 2007;Malmer et al, 2007;Rizzato et al, 2011;Sedaie Bonab et al, 2014). One of these articles, consisting of an investigation of different brain cancer types, was treated as three separate datasets in our analysis, all sharing the same group of controls.…”

Section: Study Inclusion and Characteristicsmentioning

confidence: 99%

Association between the WRAP53 gene rs2287499 C>G polymorphism and cancer risk: A meta-analysis

et al. 2016

View full text Add to dashboard Cite

ABSTRACT. The TP53 5'-untranslated region flanking the gene WRAP53 (also known as WDR79 and TCAB1) has been hypothesized to be associated with cancer risk due to its critical function in regulating p53 levels. In this review, we analyzed the association between the WRAP53 gene rs2287499 C>G polymorphism and risk of cancer using five case-control studies, comprising seven datasets. All analyses were performed using RevMan software. In the overall analysis, no significant association between rs2287499 and risk of cancer was found. We then conducted subgroup tests, stratifying the data by cancer type, ethnicity, sample source, and quality score. Only the brain and breast cancer subgroups returned significant results, but with conflicting implications. Our concerns regarding this are discussed in detail. In conclusion, the rs2287499 polymorphism may be associated with risk of cancer. Further studies taking into consideration a broader range of cancer types and different ethnicities are warranted.

show abstract

“…We identified 10 reports that evaluated the association of p53 Arg72Pro and glioma susceptibility (Wang et al, 2004;Parhar et al, 2005;Malmer et al, 2005Malmer et al, , 2007Rajaraman et al, 2007;Idbaih et al, 2008;Lima-Ramos et al, 2008;Pinto et al, 2008;El Hallani et al, 2009;and Jha et al, 2011;see Table 1). Included were 2587 cases and 4061 controls, and all data were used in the current meta-analysis.…”

Section: Association Between P53 Arg72pro and Glioma Susceptibilitymentioning

confidence: 99%

Association of p53 Arg72Pro and MDM2 SNP309 polymorphisms with glioma

Sh²,

Xh³

et al. 2012

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Epidemiological studies of the association of variants p53 Arg72Pro and MDM2 single-nucleotide polymorphism 309 (SNP309) with glioma risk have produced inconsistent results. The aim of the current study was to evaluate the association of these 2 variants with glioma susceptibility using a meta-analysis approach. For p53 Arg72Pro, 10 case-control studies including 2587 glioma patients and 4061 unrelated controls were identified. The pooled odds ratios (ORs) for Arg/Pro heterozygotes and Pro/Pro homozygotes were 1.08 [95% confidence interval (95%CI) = 0.85-1.37] and 1.08 (95%CI = 0.85-1.36), respectively, when compared to Arg/Arg carriers. Under the dominant effect model, Pro allele carriers also showed no significantly elevated glioma risk (pooled OR = 1.11, 95%CI = 3619 ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 11 (4): 3618-3628 (2012) p53 and MDM2 polymorphisms and glioma susceptibility 0.90-1.38), and similar results were found under the recessive-effect model (pooled OR = 1.17, 95%CI = 0.85-1.61). For variant MDM2 SNP309, 3 case-control studies including 606 cases and 309 controls were identified. A marginal association with glioma risk was found for heterozygous G/T carriers (pooled OR = 1.95, 95%CI = 1.00-3.81), whereas homozygous G/G carriers showed an increased but not significantly elevated risk of glioma (pooled OR = 2.14, 95%CI = 0.71-6.45) compared with that of T/T homozygotes. We also found no significant association between the MDM2 SNP309 polymorphism and glioma risk (pooled OR = 1.86, 95%CI = 0.94-3.67 and pooled OR = 1.25, 95%CI = 0.62-2.56, respectively) under the dominant and recessive models. Taken together, the current data suggested that the 2 polymorphisms may not contribute to glioma susceptibility.

show abstract

Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma

Abstract: This study found both positive and negative associations of haplotypes in p53 for glioblastoma and ATM for meningioma. This study provides new data that could add to our understanding of brain tumour susceptibility.

Cited by 58 publications

References 31 publications

TP53 codon 72 polymorphism and glioma risk: A meta-analysis

TP53 codon 72 polymorphism and glioma risk: A meta-analysis

Association between the WRAP53 gene rs2287499 C>G polymorphism and cancer risk: A meta-analysis

Association of p53 Arg72Pro and MDM2 SNP309 polymorphisms with glioma

Contact Info

Product

Resources

About